HTS_IL17_Psoriasis

A public, FAIR screening-to-biology dashboard integrating qHTS-style assay evidence, psoriasis omics, proteomics validation, protein model features, structural context, and grounded evidence cards.

Interpretation note: this is a public-data-shaped example for screening-to-biology prioritization. The ROR gamma qHTS layer is relevant to upstream Th17 / IL-17 biology, but it should be read as pathway-proximal screening evidence, not as a direct IL-17 peptide screen or efficacy model.

Analysis Walkthrough

  1. Start with screening evidence: use public ROR gamma qHTS and counterscreen-style data as the HTS layer for upstream Th17 biology.
  2. Filter artifacts: combine primary activity, counterscreen behavior, selectivity, and artifact flags into a screen QC score.
  3. Add disease relevance: overlay psoriasis transcriptomic evidence so screening hits are not interpreted outside disease context.
  4. Validate at protein level: add proteomics support and explicitly flag RNA/protein discordance.
  5. Localize the biology: use single-cell context to distinguish T-cell, keratinocyte, myeloid, or broad inflammatory signals.
  6. Add protein and structure context: treat protein model and structure features as interpretive support, not proof of mechanism.
  7. Make the decision auditable: generate a transparent ranking and evidence cards with limitations and next validation experiments.

Full technical walkthrough: Markdown · HTML

5 example candidates ranked
IL17A top integrated score
4 public evidence layers represented

Project Notes And Primers

Documentation Guide

A compact guide to the walkthrough, method primers, and rendered HTML notes.

Markdown · HTML

Project Plan

Review the workflow design, scoring model, and planned extensions.

Markdown · HTML

Scientific Review

See the critical review notes, biological interpretation, and next-version roadmap.

Markdown · HTML

Primers

Short background notes for HTS, psoriasis biology, proteomics, protein models, structure prediction, evidence summaries, and FAIR workflows.

HTS · IL-17 · Proteomics · Protein models · Structure · Evidence summaries · FAIR/AWS

Candidate Ranking

RankGeneProteinScoreScreen QCCell ContextLimitations
1IL17AInterleukin 17A0.806moderate_screen_supportT cellsNo major limitation flagged beyond compact public example-data scope.
2RORCRAR-related orphan receptor gamma0.774strong_screen_supportT cellsweak protein-level support; pathway-proximal qHTS, not direct IL-17 peptide screen
3IL23RInterleukin 23 receptor0.683moderate_screen_supportT cellsNo major limitation flagged beyond compact public example-data scope.
4STAT3Signal transducer and activator of transcription 30.563weak_screen_supportKeratinocytes and immune cellsweak protein-level support
5TNFTumor necrosis factor0.505artifact_riskMyeloid cells and T cellscounterscreen artifact risk

Score Breakdown

Screening vs Disease Evidence

Grounded Evidence Cards

IL17A

Summary: IL17A ranks #1 with a transparent score of 0.806. The candidate combines moderate_screen_support screening evidence, disease score 0.95, proteomics score 0.87, and T cells cell-type context. This is a hypothesis-generating prioritization result, not proof of therapeutic efficacy.

Limitations: No major limitation flagged beyond compact public example-data scope.

Next validation: Validate pathway modulation in a psoriasis-relevant keratinocyte/immune co-culture assay with orthogonal protein readouts.

PubChem AID2604/AID2546; GSE54456; PXD021673; GSE162183

RORC

Summary: RORC ranks #2 with a transparent score of 0.774. The candidate combines strong_screen_support screening evidence, disease score 0.78, proteomics score 0.48, and T cells cell-type context. This is a hypothesis-generating prioritization result, not proof of therapeutic efficacy.

Limitations: weak protein-level support; pathway-proximal qHTS, not direct IL-17 peptide screen

Next validation: Validate pathway modulation in a psoriasis-relevant keratinocyte/immune co-culture assay with orthogonal protein readouts.

PubChem AID2604/AID2546; GSE54456; PXD021673; GSE162183

IL23R

Summary: IL23R ranks #3 with a transparent score of 0.683. The candidate combines moderate_screen_support screening evidence, disease score 0.86, proteomics score 0.62, and T cells cell-type context. This is a hypothesis-generating prioritization result, not proof of therapeutic efficacy.

Limitations: No major limitation flagged beyond compact public example-data scope.

Next validation: Validate pathway modulation in a psoriasis-relevant keratinocyte/immune co-culture assay with orthogonal protein readouts.

PubChem AID2604/AID2546; GSE54456; PXD021673; GSE162183

STAT3

Summary: STAT3 ranks #4 with a transparent score of 0.563. The candidate combines weak_screen_support screening evidence, disease score 0.64, proteomics score 0.45, and Keratinocytes and immune cells cell-type context. This is a hypothesis-generating prioritization result, not proof of therapeutic efficacy.

Limitations: weak protein-level support

Next validation: Test specificity of pathway modulation and separate broad signaling effects from disease-selective biology.

PubChem AID2604/AID2546; GSE54456; PXD021673; GSE162183

TNF

Summary: TNF ranks #5 with a transparent score of 0.505. The candidate combines artifact_risk screening evidence, disease score 0.73, proteomics score 0.70, and Myeloid cells and T cells cell-type context. This is a hypothesis-generating prioritization result, not proof of therapeutic efficacy.

Limitations: counterscreen artifact risk

Next validation: Run focused counterscreens to distinguish broad inflammation from specific IL-17 pathway modulation.

PubChem AID2604/AID2546; GSE54456; PXD021673; GSE162183